Search | Page 12 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. MEDALIST Trial

    ... MDS disease (eg, immune-modulatory drug [IMiDs such as lenalidomide ], hypomethylating agents, or immunosuppressive therapy [IST]). ...

    Clinical Trial last updated 02/22/2017 - 11:42am.

  2. MDS and Inflammation

    ... (AML). His pioneering work led to the development of lenalidomide (Revlimid®) from the laboratory to clinical trials, which ...

    Interview last updated 02/14/2017 - 8:52am.

  3. A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

    ... failed to respond to or progressed on treatment with lenalidomide j. Eastern Cooperative Oncology Group (ECOG) performance ... Treatment with cytarabine at any dose, lenalidomide , or any other therapy targeted for the treatment of MDS (other ...

    Clinical Trial last updated 11/29/2016 - 8:29am.

  4. San Diego Family Takes Action for Awareness

    ... drugs, azacitidine , decitabine , and lenalidomide – noting of course that the latter was on for the 5q ...

    Patient Chronicle last updated 10/26/2016 - 11:42am.

  5. More is better: Combination therapies for myelodysplastic syndromes

    ... are currently three FDA-approved medications for MDS: lenalidomide , azacitidine , and decitabine .  Although these ... and acceptable side-effect profiles. -Azacitidine and lenalidomide, two FDA approved drugs in MDS, have also been combined with ...

    Research Review last updated 05/02/2016 - 9:14am.

  6. New therapeutics for myelodysplastic syndromes

    ... with myelodysplastic syndromes (MDS), including lenalidomide (Revlimidâ) and the azanucleosides, azacitidine ... Efforts are also underway to improve the effectiveness of lenalidomide, a drug with preferential activity in the group of MDS patients ...

    Research Review last updated 05/02/2016 - 9:28am.

  7. Recent developments in myelodysplastic syndromes

    ... – 2006 ( azacitidine , decitabine , and lenalidomide ), none of these are curative.  In addition, no new drugs have ... with chromosome 5q deletions are more likely to respond to lenalidomide. -High-resolution genome-wide techniques can detect ...

    Research Review last updated 05/02/2016 - 9:16am.

  8. Infections in myelodysplastic syndromes: a review

    ... drugs (5-azacytidine and decitabine ) and lenalidomide in recent years for treating MDS has affected the natural ... age and neutropenia did not increase risk. Lenalidomide therapy can be a double-edged sword. While profound neutropenia ...

    Research Review last updated 05/02/2016 - 9:28am.

  9. Clone of Patients

    ...

    Page last updated 03/14/2016 - 6:05pm.

  10. Alan List, MD

    ... (AML). His pioneering work led to the development of lenalidomide (Revlimid®) from the laboratory to clinical trials, which ...

    Leadership Award last updated 05/02/2016 - 12:18pm.